Cardiovascular Diseases during Pregnancy

Publication Date: 2018

Chairperson: Vera Regitz-Zagrosek & Jolien W Roos-Hesselink

Pregnancy, Cardiovascular disease, Risk assessment, Management, Congenital heart disease, Valvular heart disease, Hypertension, Heart failure, Arrhythmia, Pulmonary hypertension, Aortic pathology, Cardiomyopathy, Drug therapy, Pharmacology

Pocket Guidelines on the Management of Cardiovascular Disease during Pregnancy

Link

2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)

Link

“Pregnancy is complicated by maternal disease in 1–4% of cases. New data about the prevalence and incidence of pregnancy-related heart disease are limited from most parts of the world. Sudden adult death syndrome, peripartum cardiomyopathy (PPCM), aortic dissection, and myocardial infarction (MI) were the most common causes of maternal death in the UK over the period 2006–08. Knowledge of the risks associated with CVDs during pregnancy and their management in pregnant women who suffer from serious pre-existing conditions is of pivotal importance for advising patients before pregnancy. Since all measures concern not only the mother but the foetus as well, the optimum treatment of both must be targeted. A therapy favourable for the mother can be associated with potential harm to the developing child and, in extreme cases, treatment measures that protect the survival of the mother can cause the death of the foetus. On the other hand, therapies to protect the child may lead to a suboptimal outcome for the mother. Because prospective or randomized studies are frequently absent, recommendations in these Guidelines mostly correspond to evidence level C. Therefore, registries and prospective studies are urgently needed to improve current knowledge. At the European level, the Registry Of Pregnancy And Cardiac disease (ROPAC) registry of the ESC and the European Surveillance of Congenital Anomalies network are providing data on epidemiology and drug exposure in pregnancy.”